How mice with humanised immune systems are advancing cell-based immunotherapy
Drug Discovery World
JULY 22, 2022
To mitigate these risks, clinicians are turning to other immunomodulators, such as cell-based therapies, bispecific antibodies, and cytokine treatments. Immune checkpoint inhibitors (ICIs) like pembrolizumab (Keytruda) have numerous benefits and have become a standard of treatment for many patients. Jespersen et al.
Let's personalize your content